The Side Effects of GLP-1 Weight Loss Medications Some Patients Might Not Be Aware Of

GLP-1 receptor agonist medications have fundamentally changed the weight management landscape. Injectable treatments containing semaglutide and tirzepatide have produced levels of pharmacological weight loss that were previously difficult to achieve without surgical intervention. As new formulations, including oral semaglutide options, become available, patient interest in this class of medication continues to grow.

But the conversation around GLP-1 medications has, in many cases, not kept pace with the prescribing. Patients are routinely informed about the most common gastrointestinal side effects, such as nausea, diarrhea, and constipation, which are featured in most patient information leaflets. However, a range of clinically significant effects receives far less attention. Understanding these effects before starting treatment matters not because they should deter patients from treatment, but because patients who know what to expect are better positioned to manage their weight-loss journey safely.

What These Medications Actually Do in the Body

To understand the less-discussed side effects, it is important to understand the mechanism. GLP-1 (glucagon-like peptide-1) is a hormone that is released in the gut after eating. It signals the brain to reduce appetite, stimulates insulin release, suppresses glucagon, and slows the rate at which food moves through the stomach.

These medications mimic the action of this hormone. Semaglutide, available in both injectable and oral formulations, binds to GLP-1 receptors throughout the body. Examples of semaglutide-based medications include Wegovy and Ozempic.

Tirzepatide goes a step further by also activating GIP (glucose-dependent insulinotropic polypeptide) receptors, which is understood to contribute to its greater average weight loss in clinical trials. An example of a tirzepatide-based medication is Mounjaro.

The powerful appetite suppression and metabolic effects that make these medications so impactful also underpin the side effects that patients are less commonly warned about.

Gastrointestinal Slowing

Slowed gastric emptying, the rate at which food moves from the stomach into the small intestine, is integral to how GLP-1 medications produce their appetite-suppressing effect. These medicines can delay gastric emptying, particularly during initiation and dose escalation, which contributes to earlier and longer-lasting fullness in some patients.

Some patients also report sulfur-smelling burps, often described as “rotten egg” burps. These are thought to relate to slowed digestion and gas production. However, they are not usually discussed in detail in standard patient-facing information.

Delayed gastric emptying can also affect the timing of absorption of some oral medications. This is especially relevant for medicines with a narrow therapeutic index and certain oral contraceptives. Product information for some GLP-1 medications advises that additional contraceptive precautions may be appropriate when starting treatment or increasing the dose. Patients taking oral contraceptives or other critical medications should discuss potential interactions and timing considerations with their healthcare provider before starting treatment.

The Nutritional Risks Nobody Talks About

Significantly reduced appetite is the mechanism through which GLP-1 medications produce weight loss. It is also one of the most significant clinical risks, not because eating less is harmful in isolation, but because patients who are not proactively counseled on nutrition frequently fail to meet their protein, micronutrient, and caloric needs.

Muscle Loss

Rapid weight loss without adequate protein intake and resistance exercise leads to a loss of lean muscle mass alongside fat, a phenomenon sometimes called sarcopenic obesity. Clinical trial data on semaglutide have shown that a meaningful proportion of weight lost on GLP-1 medications can come from lean tissue rather than fat alone, particularly when patients are not adequately guided on nutrition.

For older patients or those already at risk of reduced muscle mass, this is a clinically important concern. Muscle loss is associated with reduced metabolic rate, which compounds the difficulty of weight maintenance over time.

Micronutrient Deficiencies

Patients who are eating significantly less are also consuming fewer vitamins and minerals. Deficiencies in iron, vitamin B12, vitamin D, magnesium, and zinc are among the most commonly observed in patients undergoing rapid weight loss, and GLP-1 patients are no exception. Hair loss, known as telogen effluvium, occurs when nutritional deficits and physiological stress push hair follicles into a resting phase. It is a frequently reported condition that can be emotionally distressing for some patients who are rarely warned about it.

"One of the most important things we tell patients starting GLP-1 treatment is that a suppressed appetite does not mean a suppressed nutritional need. Patients may feel they have eaten enough yet still fall significantly short of their daily protein requirements. We strongly recommend that anyone on these medications prioritize protein at every meal, consider a high-quality multivitamin and discusses their nutritional intake with their healthcare professional, particularly if they begin to notice hair thinning or persistent fatigue." - Ana Carolina Goncalves, Superintendent Pharmacist at Pharmica

Gallbladder Disease and Pancreatitis

Two side effects that appear in prescribing information but receive insufficient attention in patient-facing communications are gallbladder disease and pancreatitis.

Rapid weight loss of any kind significantly increases the risk of gallstone formation. When the body metabolizes fat quickly, the liver secretes more cholesterol into bile, raising the concentration to a level at which stones are more likely to form. Patients starting GLP-1 treatment should be aware of symptoms of gallbladder issues, including sharp pain in the upper right abdomen, pain that radiates to the shoulder, and nausea following fatty meals. Prompt medical advice should be sought if these symptoms occur.

Pancreatitis, though rare, has been reported in association with these medications. Patients with a personal or family history of pancreatitis or pancreatic conditions should discuss this risk carefully with their prescriber before commencing treatment, as this class of medication is generally contraindicated in such cases.

What Happens When You Stop: The Rebound Effect

Perhaps the least discussed aspect of GLP-1 treatment is what happens after it ends.

Clinical data is unambiguous on this point: most patients who discontinue treatment regain a significant proportion of the weight they have lost, and they do so relatively quickly.

Research has shown that weight regain often begins within weeks of stopping treatment, with many patients regaining a significant portion of the weight they initially lost over the following one to two years.

The physiological reason for this is important for patients to understand. These medications do not reset the body's metabolic set point or alter the underlying biology of appetite regulation. When treatment stops, appetite returns to its pre-treatment baseline. Food noise, the persistent cognitive preoccupation with food that many overweight patients experience, often re-emerges, and the hormonal environment reverts.

Patients who have not used the treatment period to build sustainable dietary habits and lifestyle changes are particularly vulnerable to weight regain.

This does not make GLP-1 medications less valuable. For many patients, the window of reduced appetite can be life-changing, providing space to rebuild their relationship with food and establish healthier long-term habits. But patients should enter treatment with a clear-eyed understanding that medication alone is unlikely to produce results that last beyond the duration of treatment.

Mood, Mental Health, and the Psychology of Food Noise

The reduction in food noise, a constant background preoccupation with food, hunger, and eating, is one of the most frequently cited positive effects of GLP-1 treatment. For patients who have experienced chronic hunger as a defining feature of their daily life, this can be genuinely transformative.

However, the reverse side of this is worth noting. Some patients report a dysphoric or flat relationship with food that extends beyond reduced appetite into a loss of pleasure in eating, reduced social engagement around mealtimes, and, in some cases, low mood.

The neurological links between appetite, reward pathways, and mood are complex, and the effects of sustained GLP-1 receptor activation on mood regulation are an area of ongoing research.

Patients who experience notable mood changes during treatment should raise this with their prescribing clinician, as a dose adjustment or a change in treatment approach may be appropriate.

Oral Semaglutide Formulations

Oral semaglutide formulations provide an alternative option for patients who prefer a needle-free approach. One example is the Wegovy semaglutide tablet. Unlike injectable formulations, oral semaglutide requires specific administration instructions to ensure adequate absorption.

The oral formulation introduces an additional layer of side effect and medication management that injectable GLP-1 users do not need to contend with. Because semaglutide is poorly absorbed through the gut lining in its natural form, oral formulations contain an absorption enhancer called SNAC (sodium N-[8-(2-hydroxybenzoyl) aminocaprylate]), which transiently raises the local pH in the stomach to allow absorption.

This mechanism means the medication must be taken on an empty stomach with a small amount of water, with no food, drink other than water, or other oral medications for at least 30 minutes afterward. Following these instructions is important because improper administration can significantly reduce absorption and clinical effectiveness.

How to Manage These Side Effects

For patients currently on or considering GLP-1 treatment, the following steps can meaningfully reduce the risk or severity of the less-discussed side effects:

1. Prioritize protein intake: Aim for at least 1.2–1.6 grams of protein per kilogram (2.2 pounds) of body weight daily, even when appetite is significantly suppressed. This helps preserve lean muscle mass throughout the weight loss period.
2. Take a complete multivitamin: Given the reduced dietary intake associated with appetite suppression and weight loss, supplementing with a broad-spectrum multivitamin and mineral formula is a sensible precaution for most patients.
3. Incorporate resistance exercise: Strength training two to three times per week supports muscle retention and metabolic rate, both during treatment and after cessation.
4. Eat slowly and in smaller portions: Given the degree of gastric slowing, eating quickly or in large portions significantly increases the risk of nausea, vomiting, and abdominal discomfort.
5. Report any persistent or severe abdominal pain promptly: Severe upper abdominal pain, particularly if accompanied by vomiting, should be assessed urgently due to the potential risk of pancreatitis and gallbladder disease.
6. Plan for discontinuation: Discuss with your prescribing clinician what a long-term maintenance plan looks like before starting treatment, including what lifestyle and dietary structures will support weight maintenance after the treatment period.

Featured Image generated by ChatGPT.